WATCHMAN device-related thrombus successfully treated with apixaban

  title={WATCHMAN device-related thrombus successfully treated with apixaban},
  author={Chun-Ka Wong and Pak-hei Chan and Cheung Chi Simon Lam and On Hing Kwok and Yat-yin Lam and Chung‐Wah Siu},
Rationale. [] Key Method Diagnosis: Reassessment echocardiography 3 months later found device-related thrombus. Interventions: The antithrombotic regimen was switched from dual antiplatelet therapy to apixaban. Outcomes: Reassessment echocardiography 3 months later revealed complete resolution of the device-related thrombus. Apixaban was stopped. He had dual antiplatelet therapy for 6 more months followed by life-long aspirin. There was no bleeding complication since implantation of Watchman device. Lessons…

Who Watches the “Watchman” and How Often?

A case with AF in which the patient had epistaxis, which required to hold anticoagulation and arterial embolization, and subsequently it was complicated by device-related thrombosis (DRT).

Device-Related Thrombus After Left Atrial Appendage Closure

The incidence, risk factors and time course ofDRT after LAAC are discussed, as well as the potential benefits of dedicated strategies in the management of DRT, which remain speculative, especially in patients with a contraindication to oral anticoagulants.

Acute Device-Related Thrombus after Watchman Device Implant

A case of Watchman device-related thrombus which developed 16 hours after the device placement is presented and various options for the management of acute thrombosis are discussed.



Apixaban in patients with atrial fibrillation.

In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage.

Large protruding thrombus over left atrial appendage occlusion device successfully treated with apixaban.

Left atrial appendage occlusion (LAAO) was successfully conducted with implantation of a 25-mm Amplatzer Amulet and patient was discharged with aspirin and clopidogrel.

A meta-analysis for efficacy and safety evaluation of transcatheter left atrial appendage occlusion in patients with nonvalvular atrial fibrillation

The pooled data demonstrated that transcatheter LAA occlusion was effective and safe in the patients with nonvalvular atrial fibrillation who were not suitable for lifelong antithrombotic therapy.